Anti–PD-L1 Treatment Induced Central Diabetes Insipidus
Chen Zhao(California NanoSystems Institute), Isaac Brownell(National Institute of Arthritis and Musculoskeletal and Skin Diseases), Ifechukwude Ebenuwa(National Institute of Diabetes and Digestive and Kidney Diseases), Julius Strauss(National Cancer Institute), Sri Harsha Tella(University of South Carolina), Anuhya Kommalapati(University of South Carolina), James L. Gulley(National Cancer Institute), Jaydira Del Rivero(National Institutes of Health)
Cited by 102
Related Papers
Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
|Journal of Clinical Oncology|2010|973
Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti–PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells
|Cancer Immunology Research|2015|456
Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors
|Clinical Cancer Research|2018|415
Current Landscape of Immunotherapy in Breast Cancer
|JAMA Oncology|2019|409
The Abscopal Effect Associated With a Systemic Anti-melanoma Immune Response
|International Journal of Radiation Oncology*Biology*Physics|2013|380